Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS

• Published in: Chinese Journal of Natural Medicines 2021-06, Vol.19 (6), p.473-480
• Main Authors: WEI, Wen-Long, WU, Shi-Fei, LI, Hao-Jv, LI, Zhen-Wei, QU, Hua, YAO, Chang-Liang, ZHANG, Jian-Qing, LI, Jia-Yuan, WU, Wan-Ying, GUO, De-An
• Format: Article
• Language: English
• Subjects: Characterization of chemical constituents; Corona virus disease 2019; ELISA; Huashi Baidu prescription
• ISSN: 1875-5364; 2095-6975; 1875-5364
• DOI: 10.1016/S1875-5364(21)60046-8

Huashi Baidu prescription (HSBDF), recommended in the Guideline for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Pneumonia (On Trials, the Seventh Edition), was clinically used to treat severe corona virus disease 2019 (COVID-19) with cough, blood-stained sputum, inhibited defecation, red tongue etc. symptoms. This study was aimed to elucidate and profile the knowledge on its chemical constituents and the potential anti-inflammatory effect in vitro. In the study, the chemical constituents in extract of HSBDF were characterized by UPLC-Q-TOF/MS in both negative and positive modes, and the pro-inflammatory cytokines were measured by enzyme-linked immunosorbent assays (ELISA) to determine the effects of HSBDF in lipopolysaccharide (LPS)-stimulated RAW264.7 cells. The results showed that a total of 217 chemical constituents were tentativedly characterized in HSBDF. Moreover, HSBDF could alleviate the expression levels of IL-6 and TNF-α in the cell models, indicating that the antiviral effects of HSBDF might be associated with regulation of the inflammatory cytokines production in RAW264.7 cells. We hope that the results could be served as the basic data for further study of HSBDF on anti-COVID-19 effect.